2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, White Blood Cell Disorders, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

2263 A Phase II trial of purging with elranatamab before autologous hematopoietic cell transplantation and maintenance therapy with elranatamab plus lenalidomide in newly diagnosed high-risk multiple myeloma

Qaiser Bashir, MD, Oren Pasvolsky, MD2, Neeraj Saini, MD3, Samer A Srour, MB ChB, MS4, Warren Fingrut, MD, MPH5, Yosra M. Aljawai, MD MS6, Paul Lin, MD, PhD7, Yago Nieto, MD, Ph.D8, Partow Kebriaei, MD9, Uday Popat, MD, MBA10, Jeremy Ramdial, MD11, Chitra Hosing, MD12, William Matsui, MD13, George Chen, MD14, Aidee Neumann, BSN, RN15, Ruby Delgado, BS16, Telyssa Ann Anderson, PharmD17, Jing Christine Ye, M.D., MSc18, Mahmoud R. Gaballa, MD19, Sarvari V. Yellapragada, MD20, Meera Mohan, MD, MS21, Sheeba Koshy Thomas, M.D.22, Krina Patel Jr, MD, MSc23, Robert Orlowski, MD, PhD24, Rafet Basar, MD25, Sunil Acharya, PhD26, Pinaki Banerjee, PhD27, Rejeena Shrestha, MD28, Katayoun Rezvani, MD, PhD29, Richard Champlin30, Elizabeth Shpall, MD31, Muzaffar Qazilbash, MD32
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
31 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
32 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction

Despite recent therapeutic advances, patients with high-risk multiple myeloma (HR-MM)  continue to have poor outcomes. Achieving minimal residual disease (MRD) negativity is a surrogate for improved progression-free survival (PFS) and overall survival (OS).Detection of clonal plasma cells (CPCs) in autografts pre-autologous hematopoietic cell transplantation (ASCT) predicts inferior post-ASCT outcomes. Elranatamab (Elra), a BCMA x CD3 bispecific antibody, has demonstrated deep responses and high MRD-negativity ratesin relapsed or refractory MM. We initiated a phase II trial evaluating Elra before stem cell collection as an in vivo purging strategy, followed by ASCT and post-transplant maintenance with Elra plus lenalidomide (Len) in patients with newly diagnosed HR-MM.

Methods
This is an ongoing single-center, single-arm phase II study (NCT06207799) enrolling transplant-eligible patients aged 18 to 75 years with newly diagnosed  HR-MM. High-risk disease is defined by the presence of adverse cytogenetic features including del(17p), TP53 mutation, t(4;14), t(14;16), t(14;20), 1q gain/amplification, or del(1p32). After achieving at least a partial response to induction therapy, patients receive pre-transplant Elra using a step-up schedule (12 mg on day 1, 32 mg on day 4, and 76 mg on days 8 and 15), followed by stem cell mobilization with growth factors, and subsequent ASCT. Maintenance therapy with Len + Elra [Cycle (C) 1-2: 76 mg on days 1 & 15; C3-12: 76 mg Q4 wk; C13-18: 76 mg Q8 wk; C19-22: 76 mg Q12 wk] begins between days +60 and +180 after ASCT and is continued for 3 years. MRD is assessed by next-generation flow cytometry (NGF; sensitivity 10-5) and next-generation sequencing (NGS, clonoSEQ; sensitivity 10-6).  The co-primary endpoints are (1) sustained MRD-negative complete response (CR), and (2) CPC-negative autograft collection. Secondary endpoints include stem cell mobilization and collection outcomes, engraftment, safety, MRD-negativity rates, PFS, and OS. Apheresis products were evaluated for CPCs and immune cell phenotypes by Cytometry by Time-Of-Flight (CyTOF). The planned sample size is 40 patients.

Results

At the time of analysis, 20 patients had been enrolled; 17 completed purging, 16  received ASCT, and 13 initiated maintenance therapy. Outcome data are reported for the 13 patients who began maintenance.  The median age was 59 years (range: 39–76), and seven (54%) were female. Induction therapy was Dara-RVD (n=10), Dara-KRD (n=1), DRD (n=1), CyBorD (n=1). Conditioning consisted of MEL200 in all but 2 patients, who received MEL140. The median follow-up since ASCT was 11 months. Cytokine-release syndrome (CRS) occurred in 11 (85%) patients, all grade 1-2. Immune effector cell-associated neurotoxicity syndrome (ICANS) was seen in one patient (grade 1). Three patients discontinued maintenance (two after C4 due to adverse events [optic neuritis, prolonged neutropenia]; one after C9 for logistical reasons). The most common grade ≥3 adverse event was neutropenia, occurring in 7 (54%) patients. Grade 3 infection occurred in 3 patients, all neutropenic fevers (1 during purging, 2 during maintenance). There were no ≥ grade 4 infections. No disease progression or deaths occurred. The MRD-negative stringent complete response (sCR) rate by NGF (10-5) increased from 8% (n=1) after induction to 54% (n=7) at day +100 post-ASCT and 100% (n=13) at the last follow-up. The MRD-negative sCR rate by NGS (10-6) at day +100 post-ASCT and at the last follow-up was 46% (n=6) and 85% (n=11), respectively.

CyTOF analysis of apheresis products (n=15) demonstrated high T-cell purity (mean 83% CD3+, predominantly CD4+), low regulatory T-cell frequencies (mean 2.7%),  and limited co-expression of inhibitory receptors. CD4+ naïve/central memory subsets were preserved (~50%). CPCs were undetectable in all apheresis products.  

Conclusions

In this ongoing phase II trial, pre-ASCT purging with Elra was feasible. It resulted in preservation of the immunologically competent T-cell compartment and complete clearance of detectable CPCs in all apheresis products, enabling infusion of CPC-negative stem cell grafts. Post-ASCT maintenance with Elra +  Len resulted in high rates of MRD-negative sCR in patients with HR-MM, with no disease progression or deaths observed during the current follow-up period. These early findings are particularly encouraging in this HR-MM population with historically poor outcomes.

Qaiser Bashir, MD: No relevant conflicts of interest to declare.